Health Industry

Latest KFF Health News Stories

NIH Grant Disruptions Slow Down Breast Cancer Research

KFF Health News Original

The Trump administration has made the future of federal funding for cancer research uncertain. At one groundbreaking breast cancer research lab, work that could save lives has slowed significantly.

It’s 2026 and You’re Uninsured. Now What?

KFF Health News Original

Many Americans are expected to lose ACA or Medicaid coverage in coming months and years as a result of the One Big Beautiful Bill Act and the expiration of enhanced pandemic-era subsidies that helped people afford Obamacare plans. Doctors and researchers say there are still ways to find affordable care.

Cuando el seguro médico cuesta más que la hipoteca

KFF Health News Original

A pesar de las intensas discusiones y del cierre del gobierno más largo en la historia, el Congreso permitió que los subsidios mejorados de ACA expiraran el pasado 31 de diciembre.

Es 2026 y no tienes seguro médico. ¿Y ahora qué?

KFF Health News Original

Los cambios en las políticas de salud en Washington están teniendo repercusiones en todo el país y haciendo que millones de personas pierdan su cobertura de Medicaid o de ACA. Pero hay opciones.

Blurry Line Between Medical and Vision Insurance Leaves Patient With Unexpected Bill

KFF Health News Original

A Wisconsin retiree with glaucoma needed her eyes examined. Her Medicare Advantage plan from UnitedHealthcare listed her optometrist’s clinic as in-network, but she learned the hard way that a clinic can be in-network and out-of-network at the same time.

This Teen Never Got His Day in Vaccine Court. His Former Lawyer Now Advises RFK on Its Overhaul.

KFF Health News Original

The federal government’s Vaccine Injury Compensation Program was supposed to help patients with their medical bills while protecting vaccine supply. But allies of Health and Human Services Secretary Robert F. Kennedy Jr. are routinely transferring cases from that program to launch lawsuits against drugmakers.

Medicare Advantage Insurers Face New Curbs on Overcharges in Trump Plan That Reins in Payments

KFF Health News Original

Proposed Trump administration changes to federal Medicare Advantage payments would stop health insurers from mining patient data for extra medical diagnoses that generate more bills to taxpayers even without treatment.

Doctors Increasingly See AI Scribes in a Positive Light. But Hiccups Persist.

KFF Health News Original

Patients say they find AI summaries of doctor visits user-friendly, but it’s not clear if their appointments are improving. In any case, doctors appear to be embracing the high-tech innovation.

Sick of Fighting Insurers, Hospitals Offer Their Own Medicare Advantage Plans

KFF Health News Original

Breakups between insurers and health systems, on top of plan cuts, left more than 3.7 million Medicare Advantage enrollees facing a tough choice last year: find new insurance or new doctors. But hospital systems say their Advantage plans can avert such upheaval, giving patients peace of mind.

Cansados de pelear con las aseguradoras, hospitales ofrecen sus propios planes Medicare Advantage

KFF Health News Original

Aunque los planes administrados por hospitales representan solo una pequeña porción del mercado de Medicare Advantage, su número de afiliados sigue creciendo, en línea con el aumento general de beneficiarios de ese sistema.

These 3 Policy Moves Are Likely To Change Health Care for Older People

KFF Health News Original

Two Trump administration regulatory rollbacks affect nursing home staffing and home care workers, and a new AI experiment in Medicare has alarmed eldercare advocates and congressional Democrats.

Estas medidas podrían cambiar la calidad de la atención médica de las personas mayores

KFF Health News Original

Después de décadas de lucha y presión, en 2023 la administración Biden abordó el problema crónico de la falta de personal en los centros de cuidado a largo plazo. ahora todo ha cambiado.

Los pagos de Medicaid por el tratamiento de la anemia falciforme dependerán de su éxito

KFF Health News Original

Actualmente hay dos terapias génicas aprobadas por la FDA, con costos de $2,2 millones por paciente en un caso y $3,1 millones en el otro, sin incluir el gasto de la hospitalización prolongada que requieren.